A-Alpha Bio

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology, A-Alpha Bio has distinguished itself in the biopharmaceutical landscape by developing innovative technologies aimed at improving drug discovery processes. The company's proprietary platform, AlphaSeq, allows the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. With this capability, A-Alpha Bio generates high-resolution interaction data necessary for accelerating therapeutic discovery and addressing unmet medical needs in various disease areas, including cancer, infectious diseases, and neurological disorders.

In addition to its experimental capabilities, A-Alpha Bio employs computational advancements through its AlphaBind platform, which predicts protein binding strength based on sequence data. By leveraging extensive datasets, the company facilitates the design and optimization of biologics and therapeutics. A-Alpha Bio partners with leading pharmaceutical companies to enhance therapeutic development pipelines, focusing on critical applications such as antibody discovery and molecular glue technology. Through the integration of cutting-edge techniques and a unique approach to data generation, A-Alpha Bio is on a mission to improve human health by pioneering advances in biotechnology.